West Pharma (WST) Tops Q1 EPS by 26c, provides guidance

West Pharma (NYSE: WST) reported Q1 EPS of $1.56, $0.26 better than the analyst estimate of $1.30. Revenue for the quarter came in at $695.4 million versus the consensus estimate of $670.31 million.

GUIDANCE:

West Pharma sees FY2024 EPS of $7.63-$7.88, versus the consensus of $7.63. West Pharma sees FY2024 revenue of $3-3.025 billion, versus the consensus of $3.011 billion.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• Rent the Runway (RENT) Reports Q2 Loss of $0.38/sh
• IBEX Limited (IBEX) Tops Q4 EPS by 6c; offers guidance
• Navan, Inc. (NAVN) Tops Q2 EPS by 1c, Offers Guidance